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Abstract 
AIM: To investigate the association between serum 
antibody levels and a subsequent celiac disease diag-
nosis in a large series of children and adults. 
METHODS: Besides subjects with classical gastroin-
testinal presentation of celiac disease, the study cohort 
included a substantial number of individuals with ex-
traintestinal symptoms and those found by screening 
in at-risk groups. Altogether 405 patients underwent 
clinical, serological and histological evaluations. After 
collection of data, the antibody values were further 
graded as low [endomysial (EmA) 1:5-200, transgluta-
minase 2 antibodies (TG2-ab) 5.0-30.0 U/L] and high 
(EmA 1: ≥ 500, TG2-ab ≥ 30.0 U/L), and the sero-
logical results were compared with the small intestinal 
mucosal histology and clinical presentation.
RESULTS: In total, 79% of the subjects with low and 
94% of those with high serum EmA titers showed 
small-bowel mucosal villous atrophy. Furthermore, 
96% of the 47 EmA positive subjects who had normal 
mucosal villi and remained on follow-up either subse-
quently developed mucosal atrophy while on a gluten-
containing diet, or responded positively to a gluten-
free diet.
CONCLUSION: Irrespective of the initial serum titers 
or clinical presentation, EmA positivity as such is a 
very strong predictor of a subsequent celiac disease 
diagnosis. 
© 2012 Baishideng. All rights reserved.
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INTRODUCTION
Recent serological screening studies have revealed that 
up to 1%-2% of  the Western population might be af-
fected by celiac disease[1,2]. However, due to its hetero-
geneous clinical picture the disease remains markedly 
underdiagnosed. Sensitive serum endomysial (EmA) 
and transglutaminase 2 antibodies (TG2-ab) are widely 
used as a method to select subjects for further investi-
gations, but the diagnosis is based on the presence of  
small-bowel mucosal villous atrophy and crypt hyperpla-
sia[3,4]. Unfortunately, the histological definition of  the 
disease involves several problems. First, invasive studies 
are needed to acquire the mucosal specimens. In addi-
tion, biopsy samples may be of  poor quality or wrongly 
orientated, increasing the risk of  false positive or nega-
tive results[5]. The mucosal damage may be patchy and 
missed even if  several samples are taken[6,7]. Finally, the 
histological lesion develops gradually and interpretation 
of  borderline cases can be challenging. Since particularly 
EmA and high values of  TG2-ab seem to predict celiac 
disease with a high specificity, it has been advocated that 
in seropositive subjects endoscopic studies might not al-
ways be needed to establish the diagnosis[8-15]. However, 
most studies so far have been carried out in tertiary cen-
ters with high-risk patients, and the results might not be 
applicable in everyday clinical practice. 
In our local health-care district active celiac disease 
case-finding has been carried out since the 1980s. As 
a result, a substantial part of  the patients are detected 
because of  atypical symptoms or by active risk-group 
screening, and currently about 0.7% of  the popula-
tion have a biopsy-proven diagnosis[16]. Hence, we now 
sought to establish whether the serum antibodies could 
predict subsequent celiac disease also in subjects with 
mild or atypical clinical presentation. Because of  the 
high specificity, EmA has traditionally been considered 
the gold standard for celiac disease serology, and was 
thus chosen as the primary inclusion criterion[17,18]. In 
addition, the results were compared to the widely used 
serum TG2-ab.
MATERIALS AND METHODS
The study cohort comprised consecutive EmA positive 
children and adults investigated at the Departments of  
Pediatrics and Gastroenterology and Alimentary Tract 
Surgery, Tampere University Hospital. Primary care phy-
sicians were encouraged to refer individuals with celiac 
disease suspicion for further investigations applying a 
low index of  suspicion. In addition, subjects who partici-
pated in population-based research studies were accept-
ed. In the hospital demographic data, a family history of  
celiac disease and symptoms leading to the disease suspi-
cion were recorded, and all subjects underwent extensive 
clinical, serological and histological evaluations. There-
after, voluntary EmA positive children and adults con-
tinued in the trial. Participants who showed small-bowel 
mucosal villous atrophy and crypt hyperplasia (Marsh Ⅲ) 
received a celiac disease diagnosis and were placed on a 
gluten-free diet. Subjects who had normal villi continued 
on a gluten-containing diet and were placed on regular 
serological and histological follow-up. In addition, the 
possibility to start an experimental trial with a gluten-free 
diet was offered to EmA positive individuals with nor-
mal villous structure (Marsh 0-Ⅱ). Those who consented 
were re-evaluated after one year, and if  a positive clinical, 
serological and histological response was observed, celiac 
disease diagnosis was established. Finally, serum TG2-ab 
were used for comparison in all from whom they were 
available.
Serum immunoglobulin A (IgA)-class EmA were 
measured by an indirect immunofluorescence method 
using human umbilical cord as antigen[19]. A dilution 
of  1:5 was considered positive, and positive sera were 
further diluted 1:50, 1:100, 1:200, 1:500, 1:1000, 1:2000 
and 1:4000. The antibody titers were further graded as 
low (1:5-1:200) and high (1:500-1:4000). Serum IgA-class 
TG2-ab were measured by enzyme-linked immunosor-
bent assay (ELISA) (Celikey, Phadia GmbH, Freiburg, 
Germany) according to the manufacturers’ instructions. 
Serum TG2-ab values ≥ 5.0 U were considered positive, 
and the values were further graded as low (5.0-29.9 U/L) 
and high (≥ 30 U/L)[13]. Total IgA values were tested 
in all subjects negative to the IgA class serological tests. 
In case of  IgA deficiency the corresponding antibodies 
were measured in immunoglobulin G (IgG) class.
Upon upper gastrointestinal endoscopy a minimum 
of  three forceps specimens were taken from the distal 
duodenum, and small-bowel mucosal morphology was 
determined from several well-oriented biopsy sections as 
previously described[17]. The degree of  mucosal damage 
was further graded according to the Marsh-Oberhuber 
classification, where Marsh 0 represents normal mucosa, 
MarshⅠ-Ⅱ represents increased intraepithelial lympho-
cytosis without (Ⅰ) or with (Ⅱ) hyperplastic crypts and 
Marsh Ⅲ partial (a), subtotal (b) or total (c) villous atro-
phy[20,21]. A patchy mucosal lesion was graded according 
to the most severe histological damage. 
Genotyping of  the participants for celiac disease-
associated human leukocyte antigen (HLA)-DQB1*02 
and DQB1*0302 alleles (DQ2 and DQ8) was performed 
using the DELFIA® Celiac Disease Hybridization Assay 
(PerkinElmer Life and Analytical Sciences, Wallac Oy, 
Turku, Finland) or the SSPTM DQB1 low resolution kit 
(Olerup SSP AB, Saltsjöbaden, Sweden) according to the 
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manufacturer’s instructions.
χ 2 with cross-tabulation was used for statistical analy-
sis. A P value less than 0.05 was considered statistically 
significant.
The study protocol was approved by the Ethics 
Committee of  Tampere University Hospital. All subjects 
or their parents gave written informed consent. 
RESULTS
In total, 405 EmA positive children and adults par-
ticipated in the study. In 10 subjects the quality of  the 
small-bowel biopsies was insufficient, in 14 EmA was 
determined as positive (1:5) without further dilution and 
in three subjects the clinical data were ambiguous. These 
cases were excluded from further statistical analyses. One 
patient had selective IgA deficiency and the correspond-
ing antibodies were measured in the IgG class. Gastroin-
testinal symptoms remained the primary reason for celiac 
disease suspicion, but almost half  of  the patients were 
detected on the basis of  extraintestinal symptoms or by 
screening of  at-risk groups and the population (Table 1).
By definition, all participants were positive for EmA. 
Serum TG2-ab were measured in 316 EmA positive 
subjects and proved positive in 286 (91%) of  them. 
Altogether 41% of  the participants had high EmA and 
54% high TG2-ab value defined at baseline. There was a 
significant association between serum TG2-ab level and 
clinical presentation, low antibody values being more 
common in the screen- than symptom-detected subjects 
(Table 2). A similar trend was observed with EmA, but 
the results were not statistically significant (P = 0.061). 
Small-bowel mucosal villous atrophy and crypt hy-
perplasia (Marsh Ⅲ) were found in altogether 85% of  
the EmA-positive subjects. There was a significant as-
sociation between high antibody values and more severe 
small-bowel mucosal deterioration; in total 94% of  those 
with high EmA titer evinced villous atrophy (Table 3). 
There was in this respect no significant difference be-
tween children and adults. The percentage of  subjects 
evincing severe small-bowel mucosal damage increased 
progressively with higher EmA titers, but only the high-
est titer 1:4000 was 100% predictive of  subsequent vil-
lous atrophy and crypt hyperplasia (Table 4). 
In total, 40 patients had low and 17 high serum anti-
body values without simultaneous villous atrophy (Table 
5). Irrespective of  the baseline titers, 45 (79%) of  these 
subjects (96% of  those who remained on follow-up) 
either subsequently developed villous atrophy while on a 
gluten-containing diet, or experienced a positive clinical 
and serological response and disappearance of  early mu-
cosal changes on a gluten-free diet (Table 5). The pres-
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  Female 265 (67)
  Age below 18 yr   92 (23)
  Age (yr), median (range)   40 (1-79)
  Main reason for disease suspicion
     Gastrointestinal symptoms1 166 (43)
     Anemia or malabsorption   38 (10)
     Extraintestinal symptoms2   50 (13)
     Screening in at-risk groups3   97 (24)
     Screening in the population4   39 (10)
     Unknown     5 (1)
Table 1  Demographic data on the study participants and pri-
mary reason for celiac disease suspicion  n  (%)
1Diarrhea, abdominal pain, flatulence, constipation, dyspepsia, and heart-
burn; 2Osteoporosis, infertility, aphthous stomatitis, short stature, delayed 
puberty, arthralgia, ataxia, epilepsy, fatigue, and alopecia; 3Family history 
of celiac disease, type 1 diabetes, thyroid disorders, Sjögren´s syndrome, 
and immunoglobulin A nephropathy; 4Population-based research studies 
that included serological screening.
EmA, titer TG2-ab, U/L
Low 1:5-200 High 1:≥ 500 Low 5.0-29.9 High ≥ 30
n  = 224, % n = 154, % n = 116, % n = 166, %
  Abdominal 
  symptoms 
          45 40           45 45
  Anemia or 
  malabsorption
            8 12             5 13
  Extraintestinal 
  symptoms
            9 16             5 13
  Screen-detected 
  subjects
          38 31           45 28
 = 0.061 P = 0.002
Table 2  Serum endomysial and transglutaminase 2 antibody 
values, divided according to the clinical presentation
EmA: Endomysial; TG2-ab: Transglutaminase 2 antibody.
EmA (L) TG2-ab(U/L)
Low 1:5-200 High 1:≥ 500 Low 5.0-29.9 High ≥ 30
n  = 227, % n = 156, % n = 146, % n = 169, %
  Marsh 0            5             1             4           1
  MarshⅠ-Ⅱ          16             5           16           5
  Marsh Ⅲa          22           13           24         12
  Marsh Ⅲb          28           29           31         28
  Marsh Ⅲc          29           52           25         53
P < 0.001 P < 0.001
Table 3  Association between high and low serum endomysial 
and transglutaminase 2 antibody values and small-bowel mu-
cosal morphology
EmA: Endomysial; TG2-ab: Transglutaminase 2 antibody.
  EmA titer Subjects Marsh 0-Ⅱ, n  (%) Marsh Ⅲ, n  (%)
  1: ≥ 5          372             57 (15)           315 (85)
  1: ≥ 50          323             39 (12)           284 (88)
  1: ≥ 100          282             26 (9)           256 (91)
  1: ≥ 200          243             22 (9)           221 (91)
  1: ≥ 500          155               9 (6)           146 (94)
  1: ≥ 1000            96               3 (3)             93 (97)
  1: ≥ 2000            48               2 (4)             46 (96)
  1:4000            20               0 (0)             20 (100)
Table 4  Association between endomysial antibody titers and 
small-bowel mucosal damage
EmA: Endomysial.
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ence of  the celiac disease-associated HLA-DQ2 or DQ8 
genotype was assessed in 299 EmA positive subjects and 
was found in all of  them.
DISCUSSION
In our large series consisting of  both children and adults, 
approximately half  of  the participants evinced high 
serum EmA levels, which was indicative of  subsequent 
small-bowel mucosal villous damage in up to 94% of  
them. The results showed a high antibody titer to be an 
excellent predictor of  villous atrophy and celiac disease 
also in high disease prevalence areas and in subjects with 
subtle or atypical symptoms. In the past few decades it 
has been observed that besides the classical gastroin-
testinal presentation, celiac disease patients may have a 
wide range of  different extraintestinal symptoms. The 
patients may suffer for example from arthralgia or ar-
thritis, osteoporosis, infertility and different neurological 
symptoms. In addition, screen-detected celiac patients 
may show only minor laboratory abnormalities or have 
no symptoms at all[3]. It was essential to investigate the 
performance of  the celiac autoantibodies also in these 
atypical patients, as they are frequently seen in clinical 
practice, and may in fact represent the most common 
clinical presentation of  celiac disease[16].  
In patients with classical gastrointestinal celiac disease, 
Valdimarsson et al[8] observed a 100% positive predictive 
value of  EmA for celiac disease in 19 adults, and sug-
gested that histological confirmation might not be nec-
essary in all such seropositive patients. Recently, similar 
results have been obtained with high values of  TG2-ab. 
In a study by Barker et al[10], 48 out of  49 children having 
TG2-ab more than five times the upper limit of  normal 
(ULN) had diagnostic small bowel mucosal damage. Like-
wise, Donaldson et al[11] observed a 100% positive pre-
dictive value for celiac disease by using the same cut-off  
level. In adults, Hill et al[13] suggested that TG2-ab levels 
more than ten times ULN would be exclusively indicative 
for celiac disease, and some other authors have presented 
comparable results[12].
Our findings thus largely accord with those in earlier 
studies carried out in specialized centers with high-risk 
patients having classical gastrointestinal presentation of  
celiac disease. Nevertheless, in the present study there 
was still a subpopulation of  individuals in whom the 
current histological criteria were not fulfilled. Approxi-
mately 6 % of  the participants with high and up to 21% 
of  those with low antibody values had normal small-
bowel mucosal villous structure, and in total this was 
seen in 15% of  the EmA-positive subjects. It could thus 
be argued that EmA are not sufficiently specific for a 
definite diagnosis of  celiac disease as such. Interestingly, 
however, there is an increasing body of  data showing 
that EmA positivity is a very strong predictor of  forth-
coming celiac disease also in subjects with initially nor-
mal villi[17,22-26]. In line with this conception, almost all of  
our EmA positive patients who had no structural villous 
damage either evinced a positive serological, clinical and 
histological response to a gluten-free diet, or subsequent-
ly developed villous atrophy while on a normal diet. The 
existence of  a celiac-type disorder in these individuals 
was further supported by the presence of  the relevant 
HLA type in all in whom it was measured. There is thus 
strong evidence that, irrespective of  the initially normal 
villous morphology, these EmA positive subjects are 
truly suffering from celiac disease. 
Our study is subject to some limitations. First, al-
though a high percentage of  the participants had mild or 
atypical clinical presentation, the number of  those found 
by population-based serological screening was rather 
low. Consequently, the results cannot be generalized to 
this patient group, and further studies are needed[27]. 
Secondly, the mucosal biopsies were taken from the dis-
tal duodenum as previously recommended[28]. Judging 
from recent evidence, however, villous atrophy can oc-
casionally be detected only in the bulb area of  the small 
intestine, and in theory celiac disease might in such cases 
already have been confirmed at the time of  the first bi-
opsy[7]. Nevertheless, interpretation of  bulb specimens 
may be biased on Brunner glands or peptic inflamma-
tion, and their role in the diagnostics remains controver-
sial. In addition, a patchy small-bowel mucosal lesion is 
always possible in celiac disease, which further highlights 
the importance of  serology in the diagnosis. 
Although EmA shows excellent specificity for an un-
treated celiac disease, it has certain limitations. The im-
munofluerescence method is laborious, time-consuming 
and always somewhat subjective. Since TG2-abs can 
be easily measured using a practical ELISA method, it 
would be tempting to use it instead of  EmA. Neverthe-
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Low1 EmA and 
TG2-ab, n  = 40
High EmA or 
TG2-ab, n  = 17
  Baseline
     Age, median (range), yr        39 (5-68)        39 (6-70)
     Females, n (%)        30 (75)        11 (65)
     Age below 18 yr          7 (18)          7 (41)
     Gastrointestinal symptoms        28 (70)        12 (71)
     Extraintestinal symptoms          2 (5)          4 (23)
     Screen-detected subjects        10 (25)          1 (6)
     EmA, median (range), titer     1:50 (1:5-1:200)   1:500 (1:5-1:2000)
     TG2-ab, median (range), U/L       6.3 (0-24.8)     45.5 (13.9-> 100)
     HLA DQ2 or DQ8, n (%)  33/33 (100)  16/16 (100)
     Marsh 0          9 (23)          3 (18)
     MarshⅠ-Ⅱ        31 (77)        14 (82)
  Follow-up
     Celiac disease diagnosis        29 (73)        16 (94)
        Villous atrophy later2        12 (30)          8 (47)
        Positive response to GFD        17 (43)          8 (47)
     Gluten, no villous atrophy          2 (5)          0
     Lost to follow-up          9 (22)          1 (6)
Table 5  Baseline and follow-up data on subjects with positive 
endomysial antibodies but normal small-bowel mucosal villous 
structure
1EmA titer 1: < 500, TG2-ab value < 30.0 U/L; 2Up to 10 yr of follow-up. 
EmA: Endomysial; TG2-ab: Transglutaminase 2 antibody; HLA: Human 
leukocyte antigen; GFD: Gluten-free diet.
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less, TG2-ab are measured by commercial tests which 
use different epitopes of  TG2 as antigen, and thus the 
specificity figures for the method have been somewhat 
inconsistent. Consequently, the positive predictive value 
of  TG2-ab has sometimes been rather low, particularly 
in low-risk populations[29]. TG2-ab can also be positive 
in some conditions such as in liver diseases[30]. For these 
reasons, we decided to use the more laborious and time-
consuming but celiac disease-specific EmA as the pri-
mary inclusion criterion in our series. As a consequence, 
the results should not be applied to TG2-ab positive 
EmA negative subjects. Finally, since antibody-negative 
subjects were not included in our study, the overall sensi-
tivity of  the serological tests could not be obtained. 
To conclude, EmA positivity as such is a very strong 
predictor of  a subsequent celiac disease diagnosis also 
in patients with low serum antibody titers and subtle or 
atypical clinical presentation. Judging from the findings 
here, invasive endoscopic studies might not be obliga-
tory in all such seropositive patients. 
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